ДИСФУНКЦИЯ ЭНДОТЕЛИЯ ПРИ СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЯХ: ФАКТОРЫ РИСКА, МЕТОДЫ ДИАГНОСТИКИ И КОРРЕКЦИИ

E.N. Vorobyeva, R.I. Vorobуev, E.A. Sharlaeva, M.L. Fomicheva, G.G. Sokolova, A.S. Kazizaeva, I.A. Batanina

Аннотация


Эндотелий выполняет важную роль в регуляции сосудистого тонуса, пролиферации и миграции гладкомышечных клеток, в поддержании баланса между протромботической и профибринолитической активностью. Свои эффекты эндотелий оказывает посредством выделения ряда вазоактивных веществ. К основным эндотелий зависимым вазодилататорам относятся оксид азота, простациклин и брадикинин. Они также регулируют местные процессы гемостаза и тормозят рост гладкомышечных клеток сосудов. Вазоконстрикторы, такие как эндотелин, тромбоксан А2 и ангиотензин II способствуют атерогенезу. Нарушение баланса между эндотелиальными факторами релаксации и констрикции рассматривается как дисфункция эндотелия. Целый ряд состояний, признанных факторами риска атеросклероза, тем или иным образом приводят к эндотелиальной дисфункции. В связи с этим, актуально использование показателей функции эндотелия в качестве маркеров ранних атеросклеротических изменений у лиц с факторами риска атеросклероза, еще до появления клинических признаков заболевания, а также назначения патогенетической терапии на этом этапе, что позволит улучшить прогноз пациентов.

Ключевые слова


дисфункция эндотелия; факторы риска; сердечно-сосудистые заболевания; эндотелин; оксид азота

Полный текст:

PDF

Литература


Бахтияров Р.З. Современные методы исследования функции эндотелия // Российский кардиологический журнал. – 2004. – № 2. – С. 76–79.

Вихирева О.В. Курение как фактор риска сердечно-сосудистых заболеваний: актуальность проблемы и возможности ее контроля путем лечения никотиновой зависимости (обзор литературы) // Профилактика заболеваний и укрепление здоровья. – 2003. – № 4. – С. 21–27.

Воробьева Е.Н., Бубликов Д.С., Молчанов А.В. и др. Современные представления о роли факторов риска сердечно-сосудистых заболеваний в атерогенезе// Известия АГУ. – 2012. – №3, т. – С. 24–28.

Государственный доклад о состоянии здоровья населения Российской Федерации в 2003 году // Здравоохранение Российской Федерации. – 2005. – № 5. – С. 3–19.

Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Рекомендации разработаны Комитетом экспертов Всероссийского научного общества кардиологов // Профилактика заболеваний и укрепление здоровья. – 2004. – № 5. – С. 7–33.

Дудкова В.А., Карпов Р.С. Атеросклероз сосудов сердца и головного мозга. – Томск: STT. – 2002. – 416 c.

Полонецкий О.Л., Плонецкий Л.З. Дисфункция эндотелия и атеросклероз// Медицинские новости. – 2012. – №6. – С. 6–11.

Behrendt D., Ganz P. Endothelial function: from vascular biology to clinical applications // Am J Cardiol. – 2002. – Vol. 90. – P. 40–48.

Berkels R., Egink G., Marsen T.A., Bartels H. et al. Nifedipine increases endothelial nitric oxide biovailability by antioxidative mechanisms // Hypertension. – 2001. – Vol. 37. – P. 240–245.

Byington R.P., Davis B.R., Plehn J.F., White H.D. Reduction of stroke events with pravastatin: The Prospective Pravastatin Pooling (PPP) Project // Circulation. – 2001. – Vol. 103. – P. 387–392.

Chobanian A.V., Barcis G.I., Black H.R. et al. Seventh Report of the Joint National Committe on Prevention, Detection, Evaluation, and Treatment of High Blood Pressurе // Hypertension. – 2003. – Vol. 42. – P. 1206–1252.

Cook A.B., Toli E., Gomez Y. et. al. From rest to stressed: endothelin-1 levels in young healthy smokers and non-smokers // Metabolism, 2015 Sep; 64(9):1103-11

Corretti M., Anderson T.J., Benjamin E.J. et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery // J Am Coll Cardiol. – 2000. – Vol. 39. – P. 257–265.

Davignon J., Ganz P. Role of endothelial dysfunction in atherosclerosis // Circulation. – 2004. – Vol. 109 (suppl III). – P. III27–III32.

Fornoni A., Raij L. Metabolic syndrome and endothelial dysfunction // Current Hypertension Reports. – 2005. – Vol. 7. – P. 88–95.

Green D.J., Maiorana A., O”Driscoll G., Taylor R. Effect of exercise training on endothelium-derived nitric oxide function in humans // J Physiol. – 2004. – Vol. 256. – P. 1–25.

Grundy S.M. Obesity, metabolic syndrome, and coronary atherosclerosis // Circulation. – 2002. – Vol. 105. – P. 2696–2698.

Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial // Lancet. – 2002. – Vol. 360. – P. 7–22.

Herrmann J., Lerman A. The endothelium: Dysfunction and beyond // Journal of Nuclear Cardiology. – 2001. – Vol. 8. – P. 197–206.

Hink U., Mollnau H. et al. Mechanisms underlying endothelial dysfunction in diabetes mellitus // Circ Res. – 2001. – Vol. 88. – P. E14–E22.

John S., Schmieder R.E. Impaired endothelial function in arterial hypertension and hypercholesterolemia: potential mechanisms and differences // J Hypertens. – 2000. – Vol. 18. – P. 363–374.

Jousilahti P., Vartiainen E., Tuomilehto J., Puska P. Sex, Age, Cardiovascular Risk Factors, and coronary heart disease: A Prospective Follow-Up Study of 14786 Middle-Aged Men and Women in Finland // Circulation. – 1999. Vol. 99. – P. 1465–1472.

Koschinsky M.L. Lipoprotein(a) and atherosclerosis: New perspectives on the mechanism of action of an enigmatic lipoprotein // Current Atherosclerosis Reports. – 2005. – Vol. 7. – P. 389–395.

Landmesser U., Hornig B., Drexler H. Endothelial function: a critical determinant in atherosclerosis? // Circulation. – 2004. – Vol. 109. – P. 27–33.

Lee W.H., Kim S.H., Lee Y. et al. Tumor necrosis factor receptor superfamily 14 is involved in atherogenesis by inducing proinflammatory cytokines and matrix metalloproteinases // Atheroscler Thromb Vasc Biol. – 2001. – Vol. 21. – P. 2004–2010.

Libby P., Ridker P.M. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment // Am J Med. – 2004. – Vol. 116. – P. 9–16.

Malik I., Danesh J., Whincup P. et al. Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis // Lancet. – 2001. – Vol. 358. – P. 971–976.

Oliveira G.H. Novel serologic markers of cardiovascular risk // Current Atherosclerosis Reports. – 2005. – Vol. 7. – P. 148–154.

Parenti A., Fillipi S., Amerini S., Granger H.J. et al. Inositol phosphate metabolism and nitric-oxide synthase activity in endothelial cells are involved in the vasorelaxant activity of nebivolol // J Pharmacol Exp Ther. – 2000. – Vol. 292. – P. 698–703.

Perticone F., Ceravolo R., PujiaA., Ventura G. et al. Prognostic significance of endothelial dysfunction in hypertensive patients // Circulation. – 2001. – Vol. 104. – P. 191–196.

Prescott E., Scharling H., Osler M., Schnohr P. Importance of light smoking and inhalation habits on risk of myocardial infarction and all-cause mortality. A 22 year follow up of 12 149 men and women in The Copenhagen City Heart Study // J Epidemiol Community Health. – 2002. – Vol. 56. – P. 702–706.

Rich S., McLaughlin V.V. Endothelial receptors blockers in cardiovascular disease // Circulation. – 2003. – Vol. 108. – P. 218–2190.

Ridker P.M., Buring J.E., Rifai N. Soluble P-selectin and the risk of future cardiovascular events // Circulation. – 2001. – Vol. 103. – P. 491–495.

Roberts C.K., Vaziri N.D., Wang X.Q., Barnard R.J. Enhanced NO inactivation and hypertension induced by a high-fat, refined-carbohydrate diet // Hypertension. – 2000. – Vol. 36. – P. 423–429.

Ross R. Atherosclerosis – an inflammatory disease // N Engl J Med. – 1999. – Vol. 340. – P. 115–126.

Schulze P.C., Lee R.T. Oxidative stress and atherosclerosis // Current Atherosclerosis Reports. – 2005. – Vol. 7. – P. 242–248.

Simon J.A., Hsia J., Cauley J.A., Richards C., Harris F. et al. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen-Progestin Replacement Study (HERS) // Circulation. – 2001. – Vol. 103. – P. 638–642.

Simon T, Jailon P. Hormone replacement therapy in postmenopausal women at cardiovascular risk: epidemiology and clinical trials // Eur Heart J. – Suppl. 2000. – P. G2–G6.

Sorrentino S., Landmesser U. Nonlipid-lowering effects of statins // Current Treatment Options in Cardiovascular Medicine. – 2005. – Vol. 7. – P. 459–466.

Sowers J.R. Hypertension, angiotensin II, and oxidative stress // N Engl J Med. - 2002. – Vol. 346. – P. 1999–2001.

Teerlink J.R. Endothelins: Pathophysiology and treatment implications in chronic heart failure // Current Heart Failure Reports. – 2005. – Vol. 2. – P. 191–197.

Walter D.H., Rittig K., Bahlmann F.H. et al. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenior cells // Circulation. – 2002. – Vol. 105. – P. 3017–3024.

REFERENCES

Bahtiyarov, R.Z. (2004). Sovremennye metody issledovaniya funkcii ehndoteliya. Rossijskij kardiologicheskij zhurnal. 2, 76–79. (in Russian).

Behrendt, D., Ganz, P. (2002). Endothelial function: from vascular biology to clinical applications. Am J Cardiol. 90, 40–48.

Berkels, R., Egink, G., Marsen, T.A., Bartels, H. (2001). Nifedipine increases endothelial nitric oxide biovailability by antioxidative mechanisms. Hypertension. 37, 240–245.

Byington, R.P., Davis, B.R., Plehn, J.F., White, H.D. (2001). Reduction of stroke events with pravastatin: The Prospective Pravastatin Pooling (PPP) Project. Circulation. 103, 387–392.

Chobanian, A.V., Barcis, G.I., Black, H.R. (2003). Seventh Report of the Joint National Committe on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 42, 1206–1252.

Cook, A.B., Toli, E., Gomez, Y. (2015). From rest to stressed: endothelin-1 levels in young healthy smokers and non-smokers. Metabolism. 64(9), 1103-11

Corretti, M., Anderson, T.J., Benjamin, E.J. (2000). Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery. J Am Coll Cardiol. 39, 257–265.

Davignon, J., Ganz, P. (2004). Role of endothelial dysfunction in atherosclerosis. Circulation. 109 (suppl III), III27–III32.

Diagnostika i korrekciya narushenij lipidnogo obmena s cel'yu profilaktiki i lecheniya ateroskleroza. Rekomendacii razrabotany Komitetom ehkspertov Vserossijskogo nauchnogo obshchestva kardiologov (2004). Profilaktika zabolevanij i ukreplenie zdorov'ya. 5, 7–33. (in Russian).

Dudkova, V.A., Karpov, R.S. (2002). Ateroskleroz sosudov serdca i golovnogo mozga. Tomsk: STT. (in Russian).

Fornoni, A., Raij, L. (2005). Metabolic syndrome and endothelial dysfunction. Current Hypertension Reports. 7, 88–95.

Gosudarstvennyj doklad o sostoyanii zdorov'ya naseleniya Rossijskoj Federacii v 2003 godu. (2005). Zdravoohranenie Rossijskoj Federacii. 5, 3–19. (in Russian).

Green, D.J., Maiorana, A., O”Driscoll, G., Taylor, R. (2004). Effect of exercise training on endothelium-derived nitric oxide function in humans. J Physiol. 256, 1–25.

Grundy, S.M. (2002). Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation. 105, 2696–2698.

Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial (2002). Lancet. 360, 7–22.

Herrmann, J., Lerman, A. (2001). The endothelium: Dysfunction and beyond. Journal of Nuclear Cardiology. 8, 197–206.

Hink, U., Mollnau, H. et al. (2001). Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res. 88, E14–E22.

John, S., Schmieder, R.E. (2000). Impaired endothelial function in arterial hypertension and hypercholesterolemia: potential mechanisms and differences. J Hypertens. 18, 363–374.

Jousilahti, P., Vartiainen, E., Tuomilehto, J., Puska, P. (1999). Sex, Age, Cardiovascular Risk Factors, and coronary heart disease: A Prospective Follow-Up Study of 14786 Middle-Aged Men and Women in Finland. Circulation. 99, 1465–1472.

Koschinsky, M.L. (2005). Lipoprotein(a) and atherosclerosis: New perspectives on the mechanism of action of an enigmatic lipoprotein. Current Atherosclerosis Reports. 7, 389–395.

Landmesser, U., Hornig, B., Drexler, H. (2004). Endothelial function: a critical determinant in atherosclerosis? Circulation. 109, 27–33.

Lee, W.H., Kim, S.H., Lee, Y. (2004). Tumor necrosis factor receptor superfamily 14 is involved in atherogenesis by inducing proinflammatory cytokines and matrix metalloproteinases. Atheroscler Thromb Vasc Biol. 21, 2004–2010.

Libby, P., Ridker, P.M. (2004). Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med. 116, 9–16.

Malik, I., Danesh, J., Whincup, P. (2001). Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet. 358, 971–976.

Oliveira, G.H. (2005). Novel serologic markers of cardiovascular risk. Current Atherosclerosis Reports. 7, 148–154.

Parenti, A., Fillipi, S., Amerini, S., Granger, H.J. (2000). Inositol phosphate metabolism and nitric-oxide synthase activity in endothelial cells are involved in the vasorelaxant activity of nebivolol. J Pharmacol Exp Ther. 292, 698–703.

Perticone, F., Ceravolo, R., Pujia, A., Ventura, G. (2001). Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation. 104, 191–196.

Poloneckij, O.L., Ploneckij, L.Z. (2012). Disfunkciya ehndoteliya i ateroskleroz. Medicinskie novosti. 6, 6–11. (in Russian).

Prescott, E., Scharling, H., Osler, M., Schnohr, P. (2002). Importance of light smoking and inhalation habits on risk of myocardial infarction and all-cause mortality. A 22 year follow up of 12 149 men and women in The Copenhagen City Heart Study. J Epidemiol Community Health. 56, 702–706.

Rich, S., McLaughlin, V.V. (2003). Endothelial receptors blockers in cardiovascular disease. Circulation. 108, 218–2190.

Ridker, P.M., Buring, J.E., Rifai, N. (2001). Soluble P-selectin and the risk of future cardiovascular events. Circulation. 103, 491–495.

Roberts, C.K., Vaziri, N.D., Wang, X.Q., Barnard, R.J. (2000). Enhanced NO inactivation and hypertension induced by a high-fat, refined-carbohydrate diet. Hypertension. 36, 423–429.

Ross, R. (1999). Atherosclerosis – an inflammatory disease. N Engl J Med. 340, 115–126.

Schulze, P.C., Lee, R.T. (2005). Oxidative stress and atherosclerosis. Current Atherosclerosis Reports. 7, 242–248.

Simon, J.A., Hsia, J., Cauley, J.A., Richards, C., Harris, F. (2001). Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen-Progestin Replacement Study (HERS). Circulation. 103, 638–642.

Simon, T, Jailon, P. (2000). Hormone replacement therapy in postmenopausal women at cardiovascular risk: epidemiology and clinical trials. Eur Heart J. Suppl., G2–G6.

Sorrentino, S., Landmesser, U. (2005). Nonlipid-lowering effects of statins. Current Treatment Options in Cardiovascular Medicine. 7, 459–466.

Sowers, J.R. (2002). Hypertension, angiotensin II, and oxidative stress. N Engl J Med. 346, 1999–2001.

Teerlink, J.R. (2005). Endothelins: Pathophysiology and treatment implications in chronic heart failure. Current Heart Failure Reports. 2, 191–197.

Vihireva, O.V. (2003). Kurenie kak faktor riska serdechno-sosudistyh zabolevanij: aktual'nost' problemy i vozmozhnosti ee kontrolya putem lecheniya nikotinovoj zavisimosti (obzor literatury). Profilaktika zabolevanij i ukreplenie zdorov'ya. 4, 21–27. (in Russian).

Vorob'eva, E.N., Bubliko,v D.S., Molchanov, A.V. (2012). Sovremennye predstavleniya o roli faktorov riska serdechno-sosudistyh zabolevanij v aterogeneze. Izvestiya AGU. 3, 24–28. (in Russian).

Walter, D.H., Rittig, K., Bahlmann, F.H. (2002). Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenior cells. Circulation. 105, 3017–3024.




DOI: http://dx.doi.org/10.14258/abs.v2i1.1219

Метрики статей

Загрузка метрик ...

Metrics powered by PLOS ALM

Ссылки

  • На текущий момент ссылки отсутствуют.




(c) 2016 E.N. Vorobyeva, R.I. Vorobуev, E.A. Sharlaeva, M.L. Fomicheva, G.G. Sokolova, A.S. Kazizaeva, I.A. Batanina

Лицензия Creative Commons
Это произведение доступно по лицензии Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная.

Лицензия Creative Commons
Это произведение доступно по лицензии Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная.
ISSN: 2412-1908